Visit the Liberty Health Sciences Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.
Liberty Health Sciences is pleased by Aphria’s lock-up agreement on divestiture
Aphria secures an 18 month lock-up agreement on divestiture of Liberty stock
TORONTO, July 23, 2018 /PRNewswire/ – Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) (“Liberty” or the “Company”) is pleased to announce Aphria Inc. (“Aphria”) has entered into an 18 month lock-up or stand-still agreement with the purchasers of Aphria’s shares in Liberty. The divestiture of Liberty stock by Aphria was originally announced on February 5, 2018 as part of Aphria’s commitment to the Toronto Stock Exchange.
A group of buyers led by members of the Serruya family (“Group”) had entered into a purchase and sale agreement with Aphria to purchase all of Aphria’s shares in the Company that are not subject to Canadian Securities Exchange escrow requirements over the course of a two and a half year period. Under the CSE escrow requirements, the shares will be released from escrow in six month intervals and will be completely released by the middle of 2020. The new agreement prevents the Group from selling the next tranche of Liberty shares owned by Aphria that will become freely trading on July 26, 2018 for a period of 18 months and provides Aphria with the ability to purchase the shares back if U.S. federal laws change, subject to certain conditions including consent of the Toronto Stock Exchange. Aphria’s current ownership position is 23.6% of the issued and outstanding shares of Liberty.
We are extremely pleased that Aphria entered into the lock-up agreement with the Group. There is no question that this action will remove any uncertainty in the market surrounding the Group’s purchase of the shares and their long term commitment and endorsement of Liberty.
CEO George Scorsis
About Liberty Health Sciences Inc.
Liberty Health Sciences Inc. operates in cannabis markets focusing on improving the lives of our consumers. Liberty’s stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near- and mid-term opportunities while keeping consumers’ well-being at the forefront of what we do. Liberty has an extensive background in highly regulated industries, with expertise in becoming a low-cost producer. Liberty leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to consumers.
The most reliable, fact-based information on Liberty Health Sciences found only on its Investor Dashboard.
Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.